| P/E (FY) | — | Sales (TTM) | $116,670 |
| Earnings (TTM) | -$6.1M | ROE | −183.04% |
| Net Margin | −5569.61% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 126.81% |
| Market Cap | $10.8M | Trading Days | 842 |
| 52W High | 2.04 |
| 52W Low | 0.42 |
| % Off High | −71.40% |
| YTD | −33.92% | 1Y | −60.84% |
| 3Y | −86.71% | Since incept. (ann.) | −37.79% |
| Ann. Volatility (1Y) | 155.86% | Ann. Volatility (3Y) | 128.96% |
| Sharpe (1Y) | −0.01 | Sharpe (3Y) | 0.04 |
| Max Drawdown (1Y) | −70.71% | Max Drawdown (3Y) | −93.82% |
| Beta (3Y, vs SPY) | −2.74 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LGVN | Longeveron Inc. | $10.7M | — |
| CALC | CalciMedica, Inc. | $11.1M | — |
| XCUR | EXICURE, INC. | $11.2M | — |
| KPRX | KIORA PHARMACEUTICALS INC | $11.3M | — |
| BIVI | BIOVIE INC. | $10.3M | — |
| MBRX | Moleculin Biotech, Inc. | $11.7M | — |
| GTBP | GT Biopharma, Inc. | $12.0M | — |
| PHIO | Phio Pharmaceuticals Corp. | $12.2M | — |
| ANEB | Anebulo Pharmaceuticals, Inc. | $12.2M | — |
| VTGN | Vistagen Therapeutics, Inc. | $9.4M | — |
| COCP | Cocrystal Pharma, Inc. | $12.7M |
| LEXX | Lexaria Bioscience Corp. | $12.9M | — |
